Humacyte, Inc. (NASDAQ:HUMA) Receives $6.54 Consensus Target Price from Analysts

Humacyte, Inc. (NASDAQ:HUMA) has received a consensus rating of “Moderate Buy” from the seven brokerages that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $6.5417.

HUMA has been the topic of a number of recent analyst reports. Benchmark dropped their price objective on Humacyte from $2.00 to $1.00 and set a “speculative buy” rating on the stock in a report on Thursday, August 13th. HC Wainwright raised their target price on Humacyte from $3.00 to $4.00 and gave the company a “buy” rating in a report on Thursday, June 11th. BTIG Research restated a “buy” rating and set a $2.00 target price on shares of Humacyte in a research report on Wednesday, August 12th. TD Cowen decreased their target price on shares of Humacyte from $1.50 to $1.25 and set a “buy” rating on the stock in a research report on Wednesday, June 17th. Finally, Wall Street Zen cut shares of Humacyte from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th.

Humacyte Price Performance

Shares of NASDAQ:HUMA opened at $0.57 on Friday. Humacyte has a 52 week low of $0.53 and a 52 week high of $2.55. The company has a 50-day moving average price of $0.66 and a 200 day moving average price of $0.84. The company has a market cap of $157.68 million, a P/E ratio of -1.16 and a beta of 2.45. The company has a quick ratio of 5.74, a current ratio of 6.21 and a debt-to-equity ratio of 2.07.

Humacyte (NASDAQ:HUMA) last released its earnings results on Wednesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.05). The business had revenue of $0.41 million for the quarter, compared to analyst estimates of $1.04 million. Humacyte had a negative return on equity of 983.32% and a negative net margin of 4,556.29%. Research analysts predict that Humacyte will post -0.4 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in HUMA. Prudential Financial Inc. purchased a new position in Humacyte in the second quarter valued at about $28,000. Price T Rowe Associates Inc. MD boosted its stake in shares of Humacyte by 21.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 76,017 shares of the company’s stock worth $73,000 after acquiring an additional 13,175 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Humacyte by 41.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 45,960 shares of the company’s stock worth $96,000 after acquiring an additional 13,407 shares in the last quarter. Financial Advisors Network Inc. acquired a new stake in shares of Humacyte in the 2nd quarter worth approximately $28,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Humacyte by 25.5% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 76,975 shares of the company’s stock worth $161,000 after acquiring an additional 15,649 shares during the period. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.